JP2006502240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502240A5 JP2006502240A5 JP2005500061A JP2005500061A JP2006502240A5 JP 2006502240 A5 JP2006502240 A5 JP 2006502240A5 JP 2005500061 A JP2005500061 A JP 2005500061A JP 2005500061 A JP2005500061 A JP 2005500061A JP 2006502240 A5 JP2006502240 A5 JP 2006502240A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- disease
- vector system
- eoi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010099 disease Diseases 0.000 claims description 39
- 210000004027 cells Anatomy 0.000 claims description 34
- 101710010587 CASP13 Proteins 0.000 claims description 20
- 102100014497 GOLPH3 Human genes 0.000 claims description 20
- 101710008339 GOLPH3 Proteins 0.000 claims description 20
- 101700062818 NP Proteins 0.000 claims description 20
- 101710043203 P23p89 Proteins 0.000 claims description 20
- 241000711798 Rabies lyssavirus Species 0.000 claims description 20
- 101710034616 gVIII-1 Proteins 0.000 claims description 20
- 101700045377 mvp1 Proteins 0.000 claims description 20
- 230000001225 therapeutic Effects 0.000 claims description 14
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000001177 retroviral Effects 0.000 claims description 8
- 229920000147 Styrene maleic anhydride Polymers 0.000 claims description 7
- 238000010361 transduction Methods 0.000 claims description 7
- 230000026683 transduction Effects 0.000 claims description 7
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 241000713666 Lentivirus Species 0.000 claims description 6
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000003612 virological Effects 0.000 claims description 6
- 108020004459 Small Interfering RNA Proteins 0.000 claims description 5
- 239000002924 silencing RNA Substances 0.000 claims description 5
- 230000037177 Biodistribution Effects 0.000 claims description 4
- 210000002161 Motor Neurons Anatomy 0.000 claims description 4
- 210000003169 Central Nervous System Anatomy 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000009792 diffusion process Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 251
- 210000001328 Optic Nerve Anatomy 0.000 claims 12
- 230000004380 optic nerve Effects 0.000 claims 12
- 235000001014 amino acid Nutrition 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 9
- 235000018102 proteins Nutrition 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 206010001897 Alzheimer's disease Diseases 0.000 claims 8
- 206010024579 Lysosomal storage disease Diseases 0.000 claims 8
- 230000001363 autoimmune Effects 0.000 claims 8
- 230000002757 inflammatory Effects 0.000 claims 8
- 201000009457 movement disease Diseases 0.000 claims 8
- 201000002481 myositis Diseases 0.000 claims 8
- 230000000926 neurological Effects 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 230000002490 cerebral Effects 0.000 claims 7
- 239000004475 Arginine Substances 0.000 claims 6
- 210000004556 Brain Anatomy 0.000 claims 6
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- 230000000069 prophylaxis Effects 0.000 claims 5
- 206010065040 AIDS dementia complex Diseases 0.000 claims 4
- 108020005544 Antisense RNA Proteins 0.000 claims 4
- 108090000994 Catalytic RNA Proteins 0.000 claims 4
- 210000002808 Connective Tissue Anatomy 0.000 claims 4
- 206010070976 Craniocerebral injury Diseases 0.000 claims 4
- 206010061811 Demyelinating polyneuropathy Diseases 0.000 claims 4
- 201000005603 Fabry disease Diseases 0.000 claims 4
- 208000009796 Gangliosidosis Diseases 0.000 claims 4
- 206010018048 Gaucher's disease Diseases 0.000 claims 4
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 claims 4
- 201000001971 Huntington's disease Diseases 0.000 claims 4
- 208000005264 Motor Neuron Disease Diseases 0.000 claims 4
- 206010061296 Motor dysfunction Diseases 0.000 claims 4
- 206010028003 Motor neurone disease Diseases 0.000 claims 4
- 208000002678 Mucopolysaccharidosis Diseases 0.000 claims 4
- 206010065579 Multifocal motor neuropathy Diseases 0.000 claims 4
- 206010028417 Myasthenia gravis Diseases 0.000 claims 4
- 208000003926 Myelitis Diseases 0.000 claims 4
- 208000009025 Nervous System Disease Diseases 0.000 claims 4
- 206010029240 Neuritis Diseases 0.000 claims 4
- 210000000715 Neuromuscular Junction Anatomy 0.000 claims 4
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 4
- 208000006660 Niemann-Pick Disease Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 206010061536 Parkinson's disease Diseases 0.000 claims 4
- 210000001428 Peripheral Nervous System Anatomy 0.000 claims 4
- 208000003055 Prion Disease Diseases 0.000 claims 4
- 229920001891 Small hairpin RNA Polymers 0.000 claims 4
- 210000000278 Spinal Cord Anatomy 0.000 claims 4
- 206010072148 Stiff person syndrome Diseases 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- 208000005765 Traumatic Brain Injury Diseases 0.000 claims 4
- 206010047115 Vasculitis Diseases 0.000 claims 4
- 108090001123 antibodies Proteins 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 4
- 229920002847 antisense RNA Polymers 0.000 claims 4
- 201000009385 autoimmune disease of the nervous system Diseases 0.000 claims 4
- 230000000903 blocking Effects 0.000 claims 4
- 230000001684 chronic Effects 0.000 claims 4
- 239000003184 complementary RNA Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 239000003550 marker Substances 0.000 claims 4
- 201000011442 metachromatic leukodystrophy Diseases 0.000 claims 4
- 229920001239 microRNA Polymers 0.000 claims 4
- 239000002679 microRNA Substances 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 201000001119 neuropathy Diseases 0.000 claims 4
- 229920002033 ribozyme Polymers 0.000 claims 4
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- 230000003827 upregulation Effects 0.000 claims 4
- 229960001230 Asparagine Drugs 0.000 claims 3
- 206010003816 Autoimmune disease Diseases 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- 208000002774 Paraproteinemias Diseases 0.000 claims 3
- 210000001032 Spinal Nerves Anatomy 0.000 claims 3
- 235000009582 asparagine Nutrition 0.000 claims 3
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 3
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- 230000002463 transducing Effects 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 210000000133 Brain Stem Anatomy 0.000 claims 1
- 210000004958 Brain cells Anatomy 0.000 claims 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 claims 1
- 102000033180 ERVK-6 Human genes 0.000 claims 1
- 101710038044 ERVK-6 Proteins 0.000 claims 1
- 101710027967 ERVW-1 Proteins 0.000 claims 1
- 101710023234 Segment 5 Proteins 0.000 claims 1
- 210000002265 Sensory Receptor Cells Anatomy 0.000 claims 1
- 101700028070 VPX Proteins 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 201000007196 sexual disease Diseases 0.000 claims 1
- 108091006011 G proteins Proteins 0.000 description 4
- 102000030007 GTP-Binding Proteins Human genes 0.000 description 4
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 4
- 210000003205 Muscles Anatomy 0.000 description 4
- 102100007156 SMN1 Human genes 0.000 description 4
- 101710028394 SMN2 Proteins 0.000 description 4
- 229920001405 Coding region Polymers 0.000 description 3
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 3
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 3
- 229920001949 Transfer RNA Polymers 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000007468 X-Linked Inhibitor of Apoptosis Protein Human genes 0.000 description 2
- 108010085257 X-Linked Inhibitor of Apoptosis Protein Proteins 0.000 description 2
- 230000002424 anti-apoptotic Effects 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 210000001097 Facial Muscles Anatomy 0.000 description 1
- 102000004329 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108090000821 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102000004218 Insulin-like growth factor I Human genes 0.000 description 1
- 108090000723 Insulin-like growth factor I Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 229910017436 S2 Can Inorganic materials 0.000 description 1
- 101710024156 SNRPN Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 102000018694 gag-pol Fusion Proteins Human genes 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000000324 neuroprotective Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0223076A GB0223076D0 (en) | 2002-10-04 | 2002-10-04 | Vector system |
| GB0228314A GB0228314D0 (en) | 2002-10-04 | 2002-12-04 | Vector system |
| GB0318213A GB0318213D0 (en) | 2002-10-04 | 2003-08-04 | Vector system |
| PCT/GB2003/004260 WO2004031390A1 (en) | 2002-10-04 | 2003-10-03 | Vector system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006502240A JP2006502240A (ja) | 2006-01-19 |
| JP2006502240A5 true JP2006502240A5 (zh) | 2006-11-24 |
Family
ID=32073911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005500061A Pending JP2006502240A (ja) | 2002-10-04 | 2003-10-03 | ベクター系 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1551974A1 (zh) |
| JP (1) | JP2006502240A (zh) |
| AU (1) | AU2003271883A1 (zh) |
| WO (1) | WO2004031390A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1755647T1 (sl) * | 2004-05-27 | 2011-01-31 | Vib Vzw | Zdravljenje amiotrofiäśne lateralne skleroze |
| US8748567B2 (en) | 2006-05-22 | 2014-06-10 | Children's Medical Center Corporation | Method for delivery across the blood brain barrier |
| EP2239330A1 (en) * | 2009-04-07 | 2010-10-13 | Institut Pasteur | Neuron generation, regeneration and protection |
| WO2012147805A1 (ja) * | 2011-04-28 | 2012-11-01 | 国立大学法人名古屋大学 | 脳移行性機能性核酸及びその利用 |
| US20220267798A1 (en) * | 2019-08-08 | 2022-08-25 | Biogen Ma Inc. | Potency assays for viral vector production |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5348741A (en) * | 1987-02-03 | 1994-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Vector for recombinant poxvirus expressing rabies virus glycoprotein |
| WO2002036170A2 (en) * | 2000-11-03 | 2002-05-10 | Oxford Biomedica (Uk) Limited | Vector system for transducing the positive neurons |
| KR20010074493A (ko) * | 1998-05-22 | 2001-08-04 | 찰스 굿맨 | 레트로바이러스 전달 시스템 |
-
2003
- 2003-10-03 JP JP2005500061A patent/JP2006502240A/ja active Pending
- 2003-10-03 WO PCT/GB2003/004260 patent/WO2004031390A1/en active Application Filing
- 2003-10-03 AU AU2003271883A patent/AU2003271883A1/en not_active Abandoned
- 2003-10-03 EP EP03753721A patent/EP1551974A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005266221B2 (en) | Non-integrative and non-replicative lentivirus, preparation and uses thereof | |
| EP2575894B1 (en) | Delivery of lentiviral vectors to the brain | |
| Patil et al. | Review article on gene therapy | |
| US20230250407A1 (en) | Silencing of dux4 by recombinant gene editing complexes | |
| WO2006008074A1 (de) | Gentherapie solider tumore durch retrovirale, mit arenavirus-glykoprotein pseudotypisierte vektoren | |
| US20210260168A1 (en) | Compositions and methods of fas inhibition | |
| Puranik et al. | Exploring the role of gene therapy for neurological disorders | |
| CN115029360A (zh) | 用于治疗粘多糖贮积症iiia型的转基因表达盒 | |
| JP2006502240A5 (zh) | ||
| US10220077B2 (en) | Combination treatment for amyotrophic lateral sclerosis (ALS) | |
| US20220290157A1 (en) | Compositions and methods for treating amyotrophic lateral sclerosis | |
| Singh et al. | Therapeutic Value of Adeno Associated Virus as a Gene Therapy Vector for Parkinson's Disease–A Focused Review | |
| JP2000500986A (ja) | レトロウイルスベクターおよび遺伝子治療におけるその用途 | |
| DE602004013165T2 (de) | Chimärisches vektorsystem | |
| JP2001501815A (ja) | 非分裂細胞への形質導入が可能なレトロウイルスベクター | |
| JP2006502240A (ja) | ベクター系 | |
| Akki et al. | A Review Article on Gene Therapy | |
| US20220175962A1 (en) | Gene therapy compositions and methods for treating parkinson's disease | |
| Braun | History of Gene Therapy | |
| US20230126157A1 (en) | Mirna-485 inhibitor for gene upregulation | |
| Mader et al. | Viral vectors and other modulatory biologics | |
| CN117343153A (zh) | 一种用于治疗亨廷顿疾病的慢病毒样颗粒 | |
| WO2022236296A1 (en) | Therapy for treatment of prader-willi syndrome | |
| KR20230123926A (ko) | Dlx2 벡터 | |
| JP2023543361A (ja) | Ｎｅｕｒｏｄ１及びｄｌｘ２ベクター |